Regulatory · Reviewed 2026-06-04

What the FDA Says About Compounded Semaglutide

A plain summary of the FDA's stated positions, in conservative language, with links to the primary sources.

Quick Answer

The FDA's position is that compounded semaglutide is not an FDA-approved product, that there is no demonstrated clinical need for outsourcing facilities to compound it from bulk substances now that the shortage is resolved, and that some marketing claims (such as compounded products being identical to branded drugs) have drawn warning letters.

Key Facts

Compounded drugs are not FDA-approved and have not undergone FDA review for safety, effectiveness, or quality.
The FDA proposed excluding semaglutide from the 503B bulks list in April 2026, citing no clinical need.
The FDA has cautioned about claims that compounded GLP-1s are identical to branded products.
The FDA recognizes semaglutide base as the active form; certain salt forms are unapproved.

Primary sources

FDA announcement: fda.gov press release
Federal Register notice: federalregister.gov

This page summarizes publicly available regulatory information for general education and is not legal advice. Regulatory status is changing in 2026; confirm current details with the FDA before relying on them.

Bottom Line

The FDA's clear messages: compounded semaglutide is not FDA-approved, the bulk-compounding pathway is being closed, and marketing claims are under scrutiny. Read the primary sources and decide with a licensed prescriber.

Compounded semaglutide is not FDA-approved as a finished drug product. Compounded medications may be prescribed only when clinically appropriate and must be evaluated by a licensed prescriber. Branded medications such as Wegovy and Ozempic are FDA-approved products; compounded semaglutide is different and should not be described as FDA-approved, “generic Wegovy,” or “generic Ozempic.”